We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+31.98%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$3.11B
AUM Growth
+$217M
Cap. Flow
-$278M
Cap. Flow %
-8.93%
Top 10 Hldgs %
51.56%
Holding
91
New
16
Increased
7
Reduced
4
Closed
14

Top Buys

Rank Stock Value
1
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$76.3M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$56M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$42.7M
4
CYTK icon
Cytokinetics
CYTK
+$38.4M
5
ALGS icon
Aligos Therapeutics
ALGS
+$29.7M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$383M
2
ALLK
Allakos
ALLK
+$55M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$48.8M
4
CGEN icon
Compugen
CGEN
+$38.7M
5
QURE icon
uniQure
QURE
+$21.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.81%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBVT
51
DBV Technologies
DBVT
$799M
$13M 0.42%
753,460
– –
ESPR
52
DELISTED
Esperion Therapeutics
ESPR
$13M 0.42%
500,000
-475,000
-49% -$14.2M
AGEN
53
Agenus
AGEN
$312M
$12.7M 0.41%
203,800
– –
SPPI
54
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$11.4M 0.37%
3,333,333
– –
RNAC icon
55
Cartesian Therapeutics
RNAC
$229M
$9.95M 0.32%
109,469
– –
NUVB icon
56
Nuvation Bio
NUVB
$2.2B
$9.36M 0.3%
800,000
– –
BLU
57
DELISTED
BELLUS Health Inc.
BLU
$9.1M 0.29%
2,975,000
– –
ASMB icon
58
Assembly Biosciences
ASMB
$498M
$9.07M 0.29%
+125,000
New +$14.7M
QURE icon
59
uniQure
QURE
$3.03B
$9.03M 0.29%
250,000
-515,400
-67% -$21.7M
FSDC
60
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$7.7M 0.25%
700,000
– –
LITS
61
Lite Strategy Inc
LITS
$32.8M
$7.69M 0.25%
145,655
– –
ORIC icon
62
Oric Pharmaceuticals
ORIC
$1.15B
$6.77M 0.22%
+200,000
New +$5.74M
VINC
63
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$6.27M 0.2%
+15,000
New +$4.73M
BLSA
64
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$6M 0.19%
+500,000
New +$5.36M
MIRM icon
65
Mirum Pharmaceuticals
MIRM
$6.46B
$5.54M 0.18%
317,000
– –
JYAC
66
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$5.15M 0.17%
+500,000
New +$5.09M
KNSA icon
67
Kiniksa Pharmaceuticals
KNSA
$5.8B
$5.13M 0.17%
290,577
– –
OBIO icon
68
Orchestra BioMed
OBIO
$238M
$5.12M 0.16%
400,000
– –
TARA icon
69
Protara Therapeutics
TARA
$220M
$5.07M 0.16%
209,227
– –
MLTX icon
70
MoonLake Immunotherapeutics
MLTX
$1.57B
$4.55M 0.15%
+400,000
New +$4.25M
SYRE icon
71
Spyre Therapeutics
SYRE
$8.54B
$4.33M 0.14%
22,000
– –
LJPC
72
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.46M 0.11%
890,700
– –
GNCA
73
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.75M 0.09%
1,134,453
– –
SNCE
74
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.13M 0.07%
+10,000
New +$2.08M
CHFW.U
75
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$2.09M 0.07%
+200,000
New +$2.04M
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Boxer Capital held 91 positions worth $3.11B, up 7.5% from $2.89B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Boxer Capital withdrew a net $278M in Q4 2020, closing 14 positions and reducing 4 holdings. Its most notable exit was Immunomedics Inc, an estimated $383M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 85% a quarter earlier, followed by Financials.

Against the trend, Boxer Capital opened a new position in ARS Pharmaceuticals worth $77.6M.

  • Boxer Capital's largest Q4 2020 buy was ARS Pharmaceuticals: 1,675,377 shares worth $77.6M.
  • Boxer Capital added most to Direxion Daily S&P Biotech Bear 3X ETF in Q4 2020, an estimated $76.3M increase.
  • Boxer Capital's biggest Q4 2020 reduction was uniQure, cutting an estimated $21.7M.
  • Boxer Capital fully exited Immunomedics Inc in Q4 2020, selling an estimated $383M.
  • Boxer Capital's ten largest holdings make up 52% of its $3.11B portfolio in Q4 2020.
  • Boxer Capital opened 16 new positions and closed 14 in Q4 2020.
  • Boxer Capital's portfolio value rose 7.5% quarter-over-quarter to $3.11B.

Based on Boxer Capital's 13F filing for Q4 2020, filed 16 Feb 2021.